{"id":33516,"date":"2025-06-02T13:02:25","date_gmt":"2025-06-02T11:02:25","guid":{"rendered":"https:\/\/dupmecp2.eu\/?p=33516"},"modified":"2025-09-10T13:19:47","modified_gmt":"2025-09-10T11:19:47","slug":"umass-chan-licences-sirna-technology","status":"publish","type":"post","link":"https:\/\/dupmecp2.eu\/de\/umass-chan-licences-sirna-technology\/","title":{"rendered":"Ein neuer Schritt vorw\u00e4rts bei der Suche nach einem Heilmittel: UMass Chan lizenziert die siRNA-Technologie \u00a0"},"content":{"rendered":"<p>Die UMass Chan Medical School hat eine vielversprechende siRNA-basierte Technologie an das Start-up-Unternehmen M2DS lizenziert. M2DS widmet sich der Weiterentwicklung dieser Technologie zur Behandlung des MECP2-Duplikationssyndroms. Dies ist ein wichtiger Schritt bei der Umsetzung von Spitzenforschung in die klinische Praxis.&nbsp;<\/p>\n\n\n\n<p>Die Technologie wurde im Labor von Dr. Khvorova entwickelt, das Projekt wurde dabei von Vignesh Hariharan geleitet. Die ersten Forschungsarbeiten konnten dank der Finanzierung durch Cure MDS und den Rett Syndrome Research Trust umgesetzt werden. Die siRNA wirkt, indem sie die Boten-RNA, die f\u00fcr die \u00dcberproduktion des MeCP2-Proteins verantwortlich ist, gezielt abbaut.&nbsp;<\/p>\n\n\n\n<p>In Studien an M\u00e4usen erreichte die Dosis wirksam das Gehirn und das R\u00fcckenmark und muss m\u00f6glicherweise nur ein- oder zweimal j\u00e4hrlich verabreicht werden. Durch die Lizenzierung dieser Technologie an M2DS tritt die Therapie nun in eine Phase ein, in der sie die notwendige Unterst\u00fctzung erh\u00e4lt, um in Richtung klinischer Studien am Menschen voranzukommen.&nbsp;&nbsp;<\/p>\n\n\n\n<p>Zus\u00e4tzlich zu den laufenden klinischen Studien von Ionis und HuidaGene k\u00f6nnte dieser Meilenstein eine vielversprechende Erg\u00e4nzung der Pipeline potenzieller Behandlungen f\u00fcr diese seltene und komplexe Erkrankung darstellen.&nbsp;<\/p>\n\n\n\n<div class=\"wp-block-buttons is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button\"><a class=\"wp-block-button__link has-white-color has-text-color has-background has-link-color wp-element-button\" href=\"https:\/\/bridge.umassmed.edu\/s\/news\/news-article\/umass-chan-licenses-sirna-therapeutics-for-mecp2-duplication-syndrome-MCMWKNCJYQ25CQHF5YITTOM757HU\" style=\"border-radius:11px;background-color:#f7a13f\">Pressemitteilung<\/a><\/div>\n<\/div>\n\n\n\n<p><\/p>","protected":false},"excerpt":{"rendered":"<p>L&rsquo;\u00e9cole de m\u00e9decine UMass Chan a octroy\u00e9 une licence pour une technologie prometteuse bas\u00e9e sur le siRNA \u00e0 M2DS, une start-up visant \u00e0 faire progresser cette technologie en tant que [&hellip;]<\/p>","protected":false},"author":1,"featured_media":33517,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-33516","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-actualite"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Une nouvelle avanc\u00e9e dans la recherche d&#039;un traitement : l&#039;UMass Chan octroie une licence pour la technologie siRNA \u00a0 - DupMECP2<\/title>\n<meta name=\"description\" content=\"L&#039;\u00e9cole de m\u00e9decine UMass Chan a octroy\u00e9 une licence pour une technologie prometteuse bas\u00e9e sur le siRNA \u00e0 M2DS, une start-up visant \u00e0 faire progresser cette technologie en tant que traitement du syndrome de duplication du g\u00e8ne MECP2. Cela marque une avanc\u00e9e majeure dans la poursuite vers une application clinique.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/dupmecp2.eu\/de\/umass-chan-licences-sirna-technology\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Une nouvelle avanc\u00e9e dans la recherche d&#039;un traitement : l&#039;UMass Chan octroie une licence pour la technologie siRNA \u00a0 - DupMECP2\" \/>\n<meta property=\"og:description\" content=\"L&#039;\u00e9cole de m\u00e9decine UMass Chan a octroy\u00e9 une licence pour une technologie prometteuse bas\u00e9e sur le siRNA \u00e0 M2DS, une start-up visant \u00e0 faire progresser cette technologie en tant que traitement du syndrome de duplication du g\u00e8ne MECP2. Cela marque une avanc\u00e9e majeure dans la poursuite vers une application clinique.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/dupmecp2.eu\/de\/umass-chan-licences-sirna-technology\/\" \/>\n<meta property=\"og:site_name\" content=\"DupMECP2\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-02T11:02:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-10T11:19:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/SiRNA-UMASS.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Caroline\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"Caroline\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"2\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/\"},\"author\":{\"name\":\"Caroline\",\"@id\":\"https:\/\/dupmecp2.eu\/#\/schema\/person\/b41e8cbba153cd974ee340386af279ee\"},\"headline\":\"Une nouvelle avanc\u00e9e dans la recherche d&rsquo;un traitement : l&rsquo;UMass Chan octroie une licence pour la technologie siRNA \u00a0\",\"datePublished\":\"2025-06-02T11:02:25+00:00\",\"dateModified\":\"2025-09-10T11:19:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/\"},\"wordCount\":245,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/dupmecp2.eu\/#organization\"},\"image\":{\"@id\":\"https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/SiRNA-UMASS.jpg\",\"articleSection\":[\"Actualit\u00e9\"],\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/\",\"url\":\"https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/\",\"name\":\"Une nouvelle avanc\u00e9e dans la recherche d'un traitement : l'UMass Chan octroie une licence pour la technologie siRNA \u00a0 - DupMECP2\",\"isPartOf\":{\"@id\":\"https:\/\/dupmecp2.eu\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/SiRNA-UMASS.jpg\",\"datePublished\":\"2025-06-02T11:02:25+00:00\",\"dateModified\":\"2025-09-10T11:19:47+00:00\",\"description\":\"L'\u00e9cole de m\u00e9decine UMass Chan a octroy\u00e9 une licence pour une technologie prometteuse bas\u00e9e sur le siRNA \u00e0 M2DS, une start-up visant \u00e0 faire progresser cette technologie en tant que traitement du syndrome de duplication du g\u00e8ne MECP2. Cela marque une avanc\u00e9e majeure dans la poursuite vers une application clinique.\",\"breadcrumb\":{\"@id\":\"https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/#primaryimage\",\"url\":\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/SiRNA-UMASS.jpg\",\"contentUrl\":\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/SiRNA-UMASS.jpg\",\"width\":1080,\"height\":1080},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/dupmecp2.eu\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Actualit\u00e9\",\"item\":\"https:\/\/dupmecp2.eu\/category\/actualite\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Une nouvelle avanc\u00e9e dans la recherche d&#8217;un traitement : l&#8217;UMass Chan octroie une licence pour la technologie siRNA \u00a0\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/dupmecp2.eu\/#website\",\"url\":\"https:\/\/dupmecp2.eu\/\",\"name\":\"DupMECP2\",\"description\":\"EU\",\"publisher\":{\"@id\":\"https:\/\/dupmecp2.eu\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/dupmecp2.eu\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/dupmecp2.eu\/#organization\",\"name\":\"DupMECP2\",\"url\":\"https:\/\/dupmecp2.eu\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\/\/dupmecp2.eu\/#\/schema\/logo\/image\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"DupMECP2\"},\"image\":{\"@id\":\"https:\/\/dupmecp2.eu\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/dupmecp2.eu\/#\/schema\/person\/b41e8cbba153cd974ee340386af279ee\",\"name\":\"Caroline\",\"sameAs\":[\"https:\/\/dupmecp2.eu\"],\"url\":\"https:\/\/dupmecp2.eu\/de\/author\/417a2385dc37aa45\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Neuer Durchbruch bei der Suche nach einer Heilung: UMass Chan lizenziert siRNA-Technologie - DupMECP2","description":"Die UMass Chan School of Medicine lizenzierte eine vielversprechende, auf siRNA basierende Technologie an M2DS, ein neu gegr\u00fcndetes Unternehmen, das diese Technologie als Behandlungsmethode f\u00fcr das MECP2-Genduplikationssyndrom voranbringen will. Dies stellt einen gro\u00dfen Fortschritt bei der Verfolgung auf dem Weg zur klinischen Anwendung dar.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/dupmecp2.eu\/de\/umass-chan-licences-sirna-technology\/","og_locale":"de_DE","og_type":"article","og_title":"Une nouvelle avanc\u00e9e dans la recherche d'un traitement : l'UMass Chan octroie une licence pour la technologie siRNA \u00a0 - DupMECP2","og_description":"L'\u00e9cole de m\u00e9decine UMass Chan a octroy\u00e9 une licence pour une technologie prometteuse bas\u00e9e sur le siRNA \u00e0 M2DS, une start-up visant \u00e0 faire progresser cette technologie en tant que traitement du syndrome de duplication du g\u00e8ne MECP2. Cela marque une avanc\u00e9e majeure dans la poursuite vers une application clinique.","og_url":"https:\/\/dupmecp2.eu\/de\/umass-chan-licences-sirna-technology\/","og_site_name":"DupMECP2","article_published_time":"2025-06-02T11:02:25+00:00","article_modified_time":"2025-09-10T11:19:47+00:00","og_image":[{"width":1080,"height":1080,"url":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/SiRNA-UMASS.jpg","type":"image\/jpeg"}],"author":"Caroline","twitter_card":"summary_large_image","twitter_misc":{"Verfasst von":"Caroline","Gesch\u00e4tzte Lesezeit":"2\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/#article","isPartOf":{"@id":"https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/"},"author":{"name":"Caroline","@id":"https:\/\/dupmecp2.eu\/#\/schema\/person\/b41e8cbba153cd974ee340386af279ee"},"headline":"Une nouvelle avanc\u00e9e dans la recherche d&rsquo;un traitement : l&rsquo;UMass Chan octroie une licence pour la technologie siRNA \u00a0","datePublished":"2025-06-02T11:02:25+00:00","dateModified":"2025-09-10T11:19:47+00:00","mainEntityOfPage":{"@id":"https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/"},"wordCount":245,"commentCount":0,"publisher":{"@id":"https:\/\/dupmecp2.eu\/#organization"},"image":{"@id":"https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/#primaryimage"},"thumbnailUrl":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/SiRNA-UMASS.jpg","articleSection":["Actualit\u00e9"],"inLanguage":"de","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/","url":"https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/","name":"Neuer Durchbruch bei der Suche nach einer Heilung: UMass Chan lizenziert siRNA-Technologie - DupMECP2","isPartOf":{"@id":"https:\/\/dupmecp2.eu\/#website"},"primaryImageOfPage":{"@id":"https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/#primaryimage"},"image":{"@id":"https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/#primaryimage"},"thumbnailUrl":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/SiRNA-UMASS.jpg","datePublished":"2025-06-02T11:02:25+00:00","dateModified":"2025-09-10T11:19:47+00:00","description":"Die UMass Chan School of Medicine lizenzierte eine vielversprechende, auf siRNA basierende Technologie an M2DS, ein neu gegr\u00fcndetes Unternehmen, das diese Technologie als Behandlungsmethode f\u00fcr das MECP2-Genduplikationssyndrom voranbringen will. Dies stellt einen gro\u00dfen Fortschritt bei der Verfolgung auf dem Weg zur klinischen Anwendung dar.","breadcrumb":{"@id":"https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/#primaryimage","url":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/SiRNA-UMASS.jpg","contentUrl":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/SiRNA-UMASS.jpg","width":1080,"height":1080},{"@type":"BreadcrumbList","@id":"https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/dupmecp2.eu\/"},{"@type":"ListItem","position":2,"name":"Actualit\u00e9","item":"https:\/\/dupmecp2.eu\/category\/actualite\/"},{"@type":"ListItem","position":3,"name":"Une nouvelle avanc\u00e9e dans la recherche d&#8217;un traitement : l&#8217;UMass Chan octroie une licence pour la technologie siRNA \u00a0"}]},{"@type":"WebSite","@id":"https:\/\/dupmecp2.eu\/#website","url":"https:\/\/dupmecp2.eu\/","name":"DupMECP2","description":"EU","publisher":{"@id":"https:\/\/dupmecp2.eu\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/dupmecp2.eu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Organization","@id":"https:\/\/dupmecp2.eu\/#organization","name":"DupMECP2","url":"https:\/\/dupmecp2.eu\/","logo":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/dupmecp2.eu\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"DupMECP2"},"image":{"@id":"https:\/\/dupmecp2.eu\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/dupmecp2.eu\/#\/schema\/person\/b41e8cbba153cd974ee340386af279ee","name":"Caroline","sameAs":["https:\/\/dupmecp2.eu"],"url":"https:\/\/dupmecp2.eu\/de\/author\/417a2385dc37aa45\/"}]}},"_links":{"self":[{"href":"https:\/\/dupmecp2.eu\/de\/wp-json\/wp\/v2\/posts\/33516","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dupmecp2.eu\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dupmecp2.eu\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dupmecp2.eu\/de\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dupmecp2.eu\/de\/wp-json\/wp\/v2\/comments?post=33516"}],"version-history":[{"count":2,"href":"https:\/\/dupmecp2.eu\/de\/wp-json\/wp\/v2\/posts\/33516\/revisions"}],"predecessor-version":[{"id":33521,"href":"https:\/\/dupmecp2.eu\/de\/wp-json\/wp\/v2\/posts\/33516\/revisions\/33521"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dupmecp2.eu\/de\/wp-json\/wp\/v2\/media\/33517"}],"wp:attachment":[{"href":"https:\/\/dupmecp2.eu\/de\/wp-json\/wp\/v2\/media?parent=33516"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dupmecp2.eu\/de\/wp-json\/wp\/v2\/categories?post=33516"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dupmecp2.eu\/de\/wp-json\/wp\/v2\/tags?post=33516"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}